{"transactions":[{"id":953704,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:39:41.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":5771,"price":66.39,"value":383136.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3792739,"source":{"system":"sec-edgar","filing":"0001423029-26-000001","document":"wk-form4_1767667178.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302926000001/wk-form4_1767667178.xml","form_type":"4"}},{"id":953703,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:39:41.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":7416,"price":65.88,"value":488566.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.28 to $66.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3798510,"source":{"system":"sec-edgar","filing":"0001423029-26-000001","document":"wk-form4_1767667178.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302926000001/wk-form4_1767667178.xml","form_type":"4"}},{"id":957645,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":16545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All options were fully vested and exercisable as of January 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":6.15,"exercise_date":"2016-01-01","expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":16545},"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957644,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":35181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All options were fully vested and exercisable as of January 1, 2016."}],"balance_after":16545,"derivative":{"exercise_price":6.15,"exercise_date":"2016-01-01","expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":35181},"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957643,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":16545,"price":68.69,"value":1136476.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.10 to $69.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3805926,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957642,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":35181,"price":69.33,"value":2439098.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.09 to $69.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3822471,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957641,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":16545,"price":6.15,"value":101751.75,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3857652,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957640,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":35181,"price":6.15,"value":216363.15,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3841107,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":960281,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":2574,"price":68.85,"value":177219.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.76 to $69.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3805926,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960280,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":10012,"price":68.33,"value":684119.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.79 to $68.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3808500,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960279,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":1319,"price":68.48,"value":90325.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.40 to $68.53, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3818512,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960278,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":8147,"price":68.01,"value":554077.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.59 to $68.37, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3819831,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960277,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":3979,"price":66.67,"value":265279.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3827978,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":962585,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":1981,"price":66.3,"value":131340.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.03 to $66.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3831957,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":962584,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":982,"price":65.53,"value":64350.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.48 to $65.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3833938,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":962583,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":35750,"price":64.51,"value":2306232.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.06 to $64.84, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3834920,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":962582,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":46287,"price":63.55,"value":2941538.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.07 to $64.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3870670,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":968359,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":3221,"price":67.87,"value":218609.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.70 to $68.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3916957,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968358,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":166,"price":66.77,"value":11083.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.70 to $66.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3920178,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968357,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":1300,"price":65.77,"value":85501.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.63 to $65.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3920344,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968356,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":64.96,"value":64960.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3921644,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968355,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":6661,"price":64.29,"value":428235.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.56 to $64.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3922644,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968354,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":8476,"price":62.94,"value":533479.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.62 to $63.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3929305,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968353,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":14095,"price":62.12,"value":875581.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.72 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3937781,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968352,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":10963,"price":61.25,"value":671483.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.79 to $61.68, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3951876,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968351,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":8416,"price":60.51,"value":509252.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $59.73 to $60.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3962839,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968350,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":8147,"price":69.96,"value":569964.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.83 to $70.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3971255,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968349,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":21321,"price":69.28,"value":1477118.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.01 to $69.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3979402,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968348,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":100532,"price":68.67,"value":6903532.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.28 to $69.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":4000723,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968347,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units with a grant date December 12, 2025, which will vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":4101255,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":1173640,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-11","kind":"sale","planned":false,"acquired":false,"shares":50800,"price":11.49,"value":583692.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3921255,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173639,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-10","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":10.87,"value":543500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3972055,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173638,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":1617,"price":11.76,"value":19015.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 11.49 to $ 12.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4022055,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173637,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":3400,"price":10.75,"value":36550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 10.51 to $ 11.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4023672,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173636,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":35305,"price":9.93,"value":350578.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 9.67 to $ 10.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4027072,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1204952,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-17T21:45:33.000Z","date":"2025-03-13","kind":"sale","planned":false,"acquired":false,"shares":51425,"price":15.07,"value":774974.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4062377,"source":{"system":"sec-edgar","filing":"0001628280-25-013210","document":"wk-form4_1742247926.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025013210/wk-form4_1742247926.xml","form_type":"4"}},{"id":1204951,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-17T21:45:33.000Z","date":"2025-03-13","kind":"grant","planned":false,"acquired":true,"shares":340000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance awards granted on December 22, 2023, and certified on March 12, 2025, upon the achievement of certain performance goals."}],"balance_after":4113802,"source":{"system":"sec-edgar","filing":"0001628280-25-013210","document":"wk-form4_1742247926.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025013210/wk-form4_1742247926.xml","form_type":"4"}},{"id":1224475,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-03-05T23:32:06.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":false,"shares":133333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All options were fully vested and exercisable as of March 6, 2015."}],"balance_after":51726,"derivative":{"exercise_price":7.75,"exercise_date":"2015-03-06","expiration_date":"2025-03-06","underlying":"Common Stock","underlying_shares":133333},"source":{"system":"sec-edgar","filing":"0001628280-25-010672","document":"wk-form4_1741217520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025010672/wk-form4_1741217520.xml","form_type":"4"}},{"id":1224474,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-03-05T23:32:06.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":false,"shares":166667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All options were fully vested and exercisable as of March 6, 2015."}],"balance_after":185059,"derivative":{"exercise_price":7.75,"exercise_date":"2015-03-06","expiration_date":"2025-03-06","underlying":"Common Stock","underlying_shares":166667},"source":{"system":"sec-edgar","filing":"0001628280-25-010672","document":"wk-form4_1741217520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025010672/wk-form4_1741217520.xml","form_type":"4"}},{"id":1224473,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:06.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":133333,"price":17.02,"value":2269327.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.58 to $ 17.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3773802,"source":{"system":"sec-edgar","filing":"0001628280-25-010672","document":"wk-form4_1741217520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025010672/wk-form4_1741217520.xml","form_type":"4"}},{"id":1224472,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:06.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":166667,"price":18.03,"value":3005006.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":3907135,"source":{"system":"sec-edgar","filing":"0001628280-25-010672","document":"wk-form4_1741217520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025010672/wk-form4_1741217520.xml","form_type":"4"}},{"id":1224471,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:06.000Z","date":"2025-03-04","kind":"exercise","planned":true,"acquired":true,"shares":133333,"price":7.75,"value":1033330.75,"ownership":{"direct":true},"balance_after":4073802,"source":{"system":"sec-edgar","filing":"0001628280-25-010672","document":"wk-form4_1741217520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025010672/wk-form4_1741217520.xml","form_type":"4"}},{"id":1224470,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:06.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":true,"shares":166667,"price":7.75,"value":1291669.25,"ownership":{"direct":true},"balance_after":3940469,"source":{"system":"sec-edgar","filing":"0001628280-25-010672","document":"wk-form4_1741217520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025010672/wk-form4_1741217520.xml","form_type":"4"}},{"id":1277505,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-10T23:23:16.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":9550,"price":20.1,"value":191955.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares represent equity in lieu of part of his year-end cash bonus."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3773802,"source":{"system":"sec-edgar","filing":"0001628280-25-004708","document":"wk-form4_1739229790.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025004708/wk-form4_1739229790.xml","form_type":"4"}},{"id":1312084,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-06T23:07:32.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":11520,"price":19.05,"value":219456.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 18.76 to $19.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3764252,"source":{"system":"sec-edgar","filing":"0001628280-25-000673","document":"wk-form4_1736204845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025000673/wk-form4_1736204845.xml","form_type":"4"}},{"id":1323474,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-23T21:39:50.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":12563,"price":19.59,"value":246109.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.39 to $ 19.85, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3775772,"source":{"system":"sec-edgar","filing":"0001628280-24-052347","document":"wk-form4_1734989985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052347/wk-form4_1734989985.xml","form_type":"4"}},{"id":1324786,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-20T23:04:26.000Z","date":"2024-12-18","kind":"grant","planned":true,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares underlying restricted stock units with a grant date 12/18/24, which will vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3788335,"source":{"system":"sec-edgar","filing":"0001628280-24-052267","document":"wk-form4_1734735860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052267/wk-form4_1734735860.xml","form_type":"4"}},{"id":1324785,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-20T23:04:26.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":5799,"price":22.12,"value":128273.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.05 to $22.27, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on December 17, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3688335,"source":{"system":"sec-edgar","filing":"0001628280-24-052267","document":"wk-form4_1734735860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052267/wk-form4_1734735860.xml","form_type":"4"}},{"id":1324784,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-20T23:04:26.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":8260,"price":21.74,"value":179572.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.04, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on December 17, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3694134,"source":{"system":"sec-edgar","filing":"0001628280-24-052267","document":"wk-form4_1734735860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052267/wk-form4_1734735860.xml","form_type":"4"}},{"id":1324783,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-20T23:04:26.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":12653,"price":20.52,"value":259639.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $21.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on December 17, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3702394,"source":{"system":"sec-edgar","filing":"0001628280-24-052267","document":"wk-form4_1734735860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052267/wk-form4_1734735860.xml","form_type":"4"}},{"id":1662845,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-02T22:25:50.000Z","date":"2024-01-31","kind":"exercise","planned":true,"acquired":false,"shares":57499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All options were fully vested and exercisable as of February 6, 2015."}],"balance_after":351726,"derivative":{"exercise_price":14.54,"exercise_date":"2015-02-06","expiration_date":"2024-02-06","underlying":"Common Stock","underlying_shares":57499},"source":{"system":"sec-edgar","filing":"0001628280-24-003097","document":"wk-form4_1706912729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003097/wk-form4_1706912729.xml","form_type":"4"}},{"id":1662844,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-02T22:25:50.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":19730,"price":32.71,"value":645368.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.47 to $33.33, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3715048,"source":{"system":"sec-edgar","filing":"0001628280-24-003097","document":"wk-form4_1706912729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003097/wk-form4_1706912729.xml","form_type":"4"}},{"id":1662843,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-02T22:25:50.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":37769,"price":32.16,"value":1214651.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.85 to $32.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3734778,"source":{"system":"sec-edgar","filing":"0001628280-24-003097","document":"wk-form4_1706912729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003097/wk-form4_1706912729.xml","form_type":"4"}},{"id":1662842,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-02T22:25:50.000Z","date":"2024-01-31","kind":"exercise","planned":true,"acquired":true,"shares":57499,"price":14.54,"value":836035.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":3772547,"source":{"system":"sec-edgar","filing":"0001628280-24-003097","document":"wk-form4_1706912729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003097/wk-form4_1706912729.xml","form_type":"4"}},{"id":1689408,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T22:25:05.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":5318,"price":31.25,"value":166187.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $32.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3715048,"source":{"system":"sec-edgar","filing":"0001628280-24-000478","document":"wk-form4_1704407090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024000478/wk-form4_1704407090.xml","form_type":"4"}},{"id":1689407,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T22:25:05.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":4634,"price":30.74,"value":142449.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3720366,"source":{"system":"sec-edgar","filing":"0001628280-24-000478","document":"wk-form4_1704407090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024000478/wk-form4_1704407090.xml","form_type":"4"}},{"id":1701556,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-22T22:04:25.000Z","date":"2023-12-20","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":28.54,"value":342480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $28.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3725000,"source":{"system":"sec-edgar","filing":"0001628280-23-042646","document":"wk-form4_1703282656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023042646/wk-form4_1703282656.xml","form_type":"4"}},{"id":1754516,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-27T22:23:41.000Z","date":"2023-10-25","kind":"sale","planned":true,"acquired":false,"shares":24338,"price":24.21,"value":589222.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.97 to $24.74, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on October 22nd, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"1,765,359 shares are subject to certain performance conditions that must be satisfied in order to vest."}],"balance_after":3737000,"source":{"system":"sec-edgar","filing":"0001628280-23-035430","document":"wk-form4_1698445412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023035430/wk-form4_1698445412.xml","form_type":"4"}},{"id":1776493,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-20T22:10:16.000Z","date":"2023-09-18","kind":"exercise","planned":false,"acquired":true,"shares":57555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents first vesting date. Option vested over four years from the first vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Represents total stock options beneficially owned at various strike prices"}],"balance_after":409225,"derivative":{"exercise_price":4.75,"exercise_date":"2013-10-01","expiration_date":"2023-09-21","underlying":"Common Stock","underlying_shares":57555},"source":{"system":"sec-edgar","filing":"0001628280-23-032707","document":"wf-form4_169524780099268.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023032707/wf-form4_169524780099268.xml","form_type":"4"}},{"id":1776492,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-09-20T22:10:16.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":26232,"price":28.27,"value":741578.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $28.94, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3761338,"source":{"system":"sec-edgar","filing":"0001628280-23-032707","document":"wf-form4_169524780099268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023032707/wf-form4_169524780099268.xml","form_type":"4"}},{"id":1776491,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-09-20T22:10:16.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":31523,"price":28,"value":882644.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.54 to $28.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3787570,"source":{"system":"sec-edgar","filing":"0001628280-23-032707","document":"wf-form4_169524780099268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023032707/wf-form4_169524780099268.xml","form_type":"4"}},{"id":1776490,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-09-20T22:10:16.000Z","date":"2023-09-18","kind":"exercise","planned":false,"acquired":true,"shares":57755,"price":4.75,"value":274336.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":3819093,"source":{"system":"sec-edgar","filing":"0001628280-23-032707","document":"wf-form4_169524780099268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023032707/wf-form4_169524780099268.xml","form_type":"4"}},{"id":1903514,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-04","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents first vesting date. Option vested over four years from date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents total stock options beneficially owned at various strike prices."}],"balance_after":466980,"derivative":{"exercise_price":2.01,"exercise_date":"2013-06-01","expiration_date":"2023-05-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":1903513,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-03","kind":"exercise","planned":false,"acquired":false,"shares":54928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents first vesting date. Option vested over four years from date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents total stock options beneficially owned at various strike prices."}],"balance_after":516980,"derivative":{"exercise_price":2.01,"exercise_date":"2013-06-01","expiration_date":"2023-05-06","underlying":"Common Stock","underlying_shares":54928},"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":1903512,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-04","kind":"sale","planned":false,"acquired":false,"shares":25992,"price":40.02,"value":1040199.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $40.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3761338,"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":1903511,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-04","kind":"sale","planned":false,"acquired":false,"shares":24008,"price":38.97,"value":935591.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.47 to $39.47, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3787330,"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":1903510,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-04","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":2.01,"value":100500.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Acquired through exercise of options expiring 5/6/23. See Table II."}],"balance_after":3811338,"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":1903509,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-03","kind":"sale","planned":false,"acquired":false,"shares":54928,"price":39.14,"value":2149881.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3761338,"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":1903508,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-05T23:04:35.000Z","date":"2023-05-03","kind":"exercise","planned":false,"acquired":true,"shares":54928,"price":2.01,"value":110405.28,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Acquired through exercise of options expiring 5/6/23. See Table II."}],"balance_after":3816266,"source":{"system":"sec-edgar","filing":"0001628280-23-016223","document":"wf-form4_168332785863869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023016223/wf-form4_168332785863869.xml","form_type":"4"}},{"id":2080298,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-21T00:09:51.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":234025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 93,610 shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 12/20/22.  Includes 140,415 underlying restricted stock units, that may be earned based on the achievement of certain performance and/or market-based goals.  If the goals are not met within the required time periods, the awards will be forfeited in part of in whole."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes a total of 1,789,697 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":3720714,"source":{"system":"sec-edgar","filing":"0001209191-22-062241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122062241/doc4.xml","form_type":"4"}},{"id":2080297,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-21T00:09:51.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":18375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of stock which vested on the date of issuance."}],"balance_after":3486689,"source":{"system":"sec-edgar","filing":"0001209191-22-062241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122062241/doc4.xml","form_type":"4"}},{"id":2149654,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-29T21:15:58.000Z","date":"2022-09-27","kind":"exercise","acquired":false,"shares":1542,"price":31.21,"value":48125.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":3468314,"source":{"system":"sec-edgar","filing":"0001209191-22-051551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122051551/doc4.xml","form_type":"4"}},{"id":2149653,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-29T21:15:58.000Z","date":"2022-09-27","kind":"exercise","acquired":false,"shares":39082,"price":30.77,"value":1202553.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3469856,"source":{"system":"sec-edgar","filing":"0001209191-22-051551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122051551/doc4.xml","form_type":"4"}},{"id":2208796,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-12T23:39:57.000Z","date":"2022-07-08","kind":"disposition_to_issuer","acquired":false,"shares":551197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Modification of previously granted award from 800,000 to 248,803."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":3508938,"source":{"system":"sec-edgar","filing":"0001209191-22-041979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122041979/doc4.xml","form_type":"4"}},{"id":2209394,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-07-12T00:08:32.000Z","date":"2022-07-07","kind":"exercise","acquired":false,"shares":2501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents first vesting date. Option vested over four years from date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents total stock options beneficially owned at various strike prices."}],"balance_after":612532,"derivative":{"exercise_price":14.54,"exercise_date":"2014-03-01","expiration_date":"2024-02-06","underlying":"Common Stock","underlying_shares":2501},"source":{"system":"sec-edgar","filing":"0001209191-22-041850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122041850/doc4.xml","form_type":"4"}},{"id":2209393,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-12T00:08:32.000Z","date":"2022-07-07","kind":"exercise","acquired":true,"shares":2501,"price":14.54,"value":36364.54,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":4060135,"source":{"system":"sec-edgar","filing":"0001209191-22-041850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122041850/doc4.xml","form_type":"4"}},{"id":2399465,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-02-14T13:54:16.000Z","date":"2022-02-11","kind":"exercise","acquired":false,"shares":146388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents first vesting date. Option vested over four years from date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Represents total stock options beneficially owned at various strike prices."}],"balance_after":615033,"derivative":{"exercise_price":5.19,"exercise_date":"2012-03-01","expiration_date":"2022-02-16","underlying":"Common Stock","underlying_shares":146388},"source":{"system":"sec-edgar","filing":"0001209191-22-009052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122009052/doc4.xml","form_type":"4"}},{"id":2399464,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-14T13:54:16.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":1900,"price":50.51,"value":95969.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.49 to $50.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":4057634,"source":{"system":"sec-edgar","filing":"0001209191-22-009052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122009052/doc4.xml","form_type":"4"}},{"id":2399463,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-14T13:54:16.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":61482,"price":50.9,"value":3129433.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.58 to $51.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":4059534,"source":{"system":"sec-edgar","filing":"0001209191-22-009052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122009052/doc4.xml","form_type":"4"}},{"id":2399462,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-14T13:54:16.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":42153,"price":52.28,"value":2203758.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.60 to $51.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":4121016,"source":{"system":"sec-edgar","filing":"0001209191-22-009052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122009052/doc4.xml","form_type":"4"}},{"id":2399461,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-14T13:54:16.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":40853,"price":53.11,"value":2169702.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.63 to $53.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":4163169,"source":{"system":"sec-edgar","filing":"0001209191-22-009052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122009052/doc4.xml","form_type":"4"}},{"id":2399460,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-14T13:54:16.000Z","date":"2022-02-11","kind":"exercise","acquired":true,"shares":146388,"price":5.19,"value":759753.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":4204022,"source":{"system":"sec-edgar","filing":"0001209191-22-009052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122009052/doc4.xml","form_type":"4"}},{"id":2440713,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-01-08T02:39:27.000Z","date":"2022-01-07","kind":"exercise","acquired":false,"shares":11806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents first vesting date. Option vested over four years from date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents total stock options beneficially owned at various strike prices."}],"balance_after":761421,"derivative":{"exercise_price":5.19,"exercise_date":"2012-03-01","expiration_date":"2022-02-16","underlying":"Common Stock","underlying_shares":11806},"source":{"system":"sec-edgar","filing":"0001209191-22-002617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122002617/doc4.xml","form_type":"4"}},{"id":2440712,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-08T02:39:27.000Z","date":"2022-01-07","kind":"exercise","acquired":true,"shares":11806,"price":5.19,"value":61273.14,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":4057634,"source":{"system":"sec-edgar","filing":"0001209191-22-002617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122002617/doc4.xml","form_type":"4"}},{"id":2451945,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-05T02:22:50.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined goals related to the advancement of the Company's market capitalization that must be achieved within four years. If the goals are not met within the required time periods, the award will be forfeited in part or in whole."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":4045828,"source":{"system":"sec-edgar","filing":"0001209191-22-001284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001284/doc4.xml","form_type":"4"}},{"id":2460214,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2021-12-24T02:52:14.000Z","date":"2021-12-23","kind":"exercise","acquired":false,"shares":11806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents first vesting date. Option vested over four years from date of grant."}],"balance_after":773227,"derivative":{"exercise_price":5.19,"exercise_date":"2012-03-01","expiration_date":"2022-02-16","underlying":"Common Stock","underlying_shares":11806},"source":{"system":"sec-edgar","filing":"0001209191-21-071196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121071196/doc4.xml","form_type":"4"}},{"id":2460213,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-24T02:52:14.000Z","date":"2021-12-23","kind":"exercise","acquired":true,"shares":11806,"price":5.19,"value":61273.14,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes a total of 1,400,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole"}],"balance_after":3245828,"source":{"system":"sec-edgar","filing":"0001209191-21-071196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121071196/doc4.xml","form_type":"4"}},{"id":2468642,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-18T01:14:04.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":6989,"price":70.19,"value":490557.91,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.  Of the total 60,000 shares sold, 50,000 of the shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.96 to $70.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3219022,"source":{"system":"sec-edgar","filing":"0001209191-21-070467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121070467/doc4.xml","form_type":"4"}},{"id":2468641,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-18T01:14:04.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":9223,"price":69.52,"value":641182.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.  Of the total 60,000 shares sold, 50,000 of the shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.94 to $69.94, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3226011,"source":{"system":"sec-edgar","filing":"0001209191-21-070467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121070467/doc4.xml","form_type":"4"}},{"id":2468640,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-18T01:14:04.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":3074,"price":68.2,"value":209646.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.  Of the total 60,000 shares sold, 50,000 of the shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.82 to $68.80, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3235234,"source":{"system":"sec-edgar","filing":"0001209191-21-070467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121070467/doc4.xml","form_type":"4"}},{"id":2468639,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-18T01:14:04.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":14857,"price":67.19,"value":998241.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.  Of the total 60,000 shares sold, 50,000 of the shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.76 to $67.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3238308,"source":{"system":"sec-edgar","filing":"0001209191-21-070467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121070467/doc4.xml","form_type":"4"}},{"id":2468638,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-18T01:14:04.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":25857,"price":66.28,"value":1713801.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.  Of the total 60,000 shares sold, 50,000 of the shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.75 to $66.74, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3253165,"source":{"system":"sec-edgar","filing":"0001209191-21-070467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121070467/doc4.xml","form_type":"4"}},{"id":2536877,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-22T21:58:09.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":5830,"price":66.09,"value":385304.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.97 to $66.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes a total of 1,600,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":3279022,"source":{"system":"sec-edgar","filing":"0001209191-21-061426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121061426/doc4.xml","form_type":"4"}},{"id":2536876,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-22T21:58:09.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":44170,"price":65.57,"value":2896226.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.97 to $65.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":3284852,"source":{"system":"sec-edgar","filing":"0001209191-21-061426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121061426/doc4.xml","form_type":"4"}},{"id":2536875,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-22T21:58:09.000Z","date":"2021-10-20","kind":"sale","acquired":false,"shares":15000,"price":66.23,"value":993450.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This option exercise was completed as the underlying option was due to expire in October 2021."}],"balance_after":3329022,"source":{"system":"sec-edgar","filing":"0001209191-21-061426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121061426/doc4.xml","form_type":"4"}},{"id":2926602,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-04T23:02:39.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of eight\npredetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that\nmust be achieved within four years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in\nwhole."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 1,700,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals.\nIf the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":3344022,"source":{"system":"sec-edgar","filing":"0001209191-21-000485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121000485/doc4.xml","form_type":"4"}},{"id":2926601,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-04T23:02:39.000Z","date":"2020-12-30","kind":"gift","acquired":false,"shares":599,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2544022,"source":{"system":"sec-edgar","filing":"0001209191-21-000485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121000485/doc4.xml","form_type":"4"}},{"id":2929612,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-30T22:52:34.000Z","date":"2020-12-28","kind":"gift","acquired":false,"shares":1126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes a total of 900,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole."}],"balance_after":2544621,"source":{"system":"sec-edgar","filing":"0001209191-20-065556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120065556/doc4.xml","form_type":"4"}},{"id":2935336,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock (right to buy)","published_at":"2020-12-22T22:55:40.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":28274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents first vesting date. Option vested over four years from date of grant."}],"balance_after":800033,"derivative":{"exercise_price":6.15,"exercise_date":"2016-02-01","expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":28274},"source":{"system":"sec-edgar","filing":"0001209191-20-064897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120064897/doc4.xml","form_type":"4"}},{"id":2935335,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock (right to buy)","published_at":"2020-12-22T22:55:40.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":12236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents first vesting date. Option vested over four years from date of grant."}],"balance_after":828307,"derivative":{"exercise_price":4.75,"exercise_date":"2013-10-01","expiration_date":"2023-09-21","underlying":"Common Stock","underlying_shares":12236},"source":{"system":"sec-edgar","filing":"0001209191-20-064897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120064897/doc4.xml","form_type":"4"}}],"next_cursor":"2020-12-22T22:55:40.000000Z,2935335"}